Carcinoma, Non-Small-Cell Lung
Conditions
Brief summary
Non-Small Cell Lung Cancer(NSCLC) is the leading cause of death in Korean men after stomach cancer. Surgical resection plays a main role for curative treatment. However, less than 20 % of the NSCLC patients have been found in stage I-II disease. In inoperable stage IIIA/B disease, the recommended treatment is combined chemotherapy and radiation therapy. Various kinds of combination of 2 modalities have been used either in sequential or concurrent setting. Concurrent chemoradiotherapy(CCRT) have been recognized to have better survival than radiation therapy alone or sequential therapy, but additional consolidation chemotherapy after CCRT is not yet to be determined for the beneficial role in survival gain. Docetaxel is an anticancer drug and has synergistic anticancer effect in various cancer with cisplatin, another anticancer drug. In the present study, randomised trial will be performed to confirm the efficacy of the consolidation chemotherapy with docetaxel and cisplatin after completing CCRT with the same chemotherapeutic agents in stage III inoperable NSCLC on progression free survival and overall survival.
Interventions
DRUGconsolidation chemotherapy with Docetaxel plus cisplatin
definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
DRUGCCRT arm without consolidation chemotherapy
definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
Sponsors
Sanofi
Samsung Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven non-small cell lung cancer * Presence of measurable disease by RECIST * Inoperable Stage IIIA or IIIB, proven by CT or MRI (except wet T4). However, N2 or N3 should be confirmed by PET or pathology. (For T4, PET is optional) * 18 years of age or older * ECOG Performance status 0-1 * No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy * Serum Hgb ≥ 10 gm/dL, platelet ≥ 100,000/μL, absolute neutrophil count ≥ 1,500/μL * Serum creatinine ≤1.25 x UNL or creatinine clearance ≥60 mlmL/min * Serum bilirubin ≤ 1.5 x UNL, AST (SGOT) and ALT (SGPT) ≤ 2.5 x UNL, alkaline phosphatase ≤ 5 x UNL * FEV1\> 0.8 L * Patients must sign an informed consent
Exclusion criteria
* Carcinoid tumor, small cell carcinoma of lung * Patients with any distant metastasis * History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix * Any other morbidity or situation with contraindication for chemotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment) * Pregnant or lactating women, women who has not taken test of pregnancy (within 14 days before the first administration) and pregnant women * Women and men of childbearing potential who have no willing of employing adequate contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | The final analysis will be conducted when 381 events (progressions or deaths) are observed. |
Secondary
| Measure | Time frame |
|---|---|
| safety | The final analysis will be conducted when 381 events (progressions or deaths) are observed. |
| overall survival | The final analysis will be conducted when 381 events (progressions or deaths) are observed. |
| response rate | The final analysis will be conducted when 381 events (progressions or deaths) are observed. |
| patterns of failure | The final analysis will be conducted when 381 events (progressions or deaths) are observed. |
Countries
South Korea
Outcome results
None listed